Gilead Sciences Inc.'s measured launch of the chimeric antigen receptor T-cell (CAR-T) therapy Yescarta is proceeding as expected, with 28 cancer centers in the US now ready to provide the treatment and $7m in sales for the fourth quarter.
Jefferies analyst Michael Yee said in a same-day note that Yescarta sales were higher than expected, considering they reflected only...